Axanum Approval Status
Axanum (aspirin/esomeprazole) is an investigational low dose aspirin esomeprazole combination for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers.
In June 2010, AstraZeneca announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Axanum (aspirin/esomeprazole magnesium) tablets had not been approved.
Development Status and FDA Approval Process for Axanum
|Jun 1, 2010||AstraZeneca Receives FDA Complete Response Letter for Axanum New Drug Application|
|May 4, 2009||AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.